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Initial studies that described the novel coronavirus (COVID-19) reported increased
morbidity and mortality in patients with cancer. Of this group, patients with hematologic
malignancies (HM) had the highest disease severity and death rates. Subsequent studies
have attempted to better describe how COVID-19 affects patients with HM. However,
these studies have yielded variable and often contradictory results. We present our singleinstitution experience with patients with HM who were diagnosed with COVID-19 from
March 2020 to March 2021. We report 62 total cases with 10 patients who died during
this time. The overall mortality was 16.1%. Mortality during the ﬁrst two waves of COVID
was 27.8% and 25%. Mortality during the third wave of COVID was 10%. The median age
of patients was 67 years (range 20-89 years). 55% of patients had lymphoid malignancies
and the majority had active disease at the time of diagnosis with COVID-19. 87% of
patients had more than one co-morbidity. Important co-morbidities included
cardiovascular disease and smoking history. 38.7% of patients had asymptomatic or
mild disease, 54.8% required hospitalization, and 17.5% required ICU level care. In
patients who required ICU level care, the mortality was 60%.
Keywords: COVID-19, hematologic malignancy, lymphoma, leukemia, multiple myeloma, mortality

INTRODUCTION
The novel coronavirus (COVID-19) was ﬁrst discovered in Wuhan, China in December 2019 and
quickly escalated to a global pandemic. As of March 2021, there were over 126 million reported
cases of coronavirus and over 2.7 million COVID-related deaths (1). COVID-19 has caused an
unprecedented burden on the healthcare system and has profoundly affected healthcare delivery,
especially for patients who require close continuity of care.
Patients with cancer have increased contact with the healthcare system and, as a result, are at an
increased risk of COVID-19 infection. Furthermore, initial studies in China showed that the
frequency of severe COVID-19 infection (ICU admission, requiring invasive ventilation) and death
was higher in patients with cancer compared to the general population (2). Later studies suggested
that patients with HM are especially vulnerable and were found to have highest disease severity and
death rates among all patients with cancer (3). This may be, in part, because patients with HM often
have innate and adaptive immune dysfunction (4). In B-cell neoplasms, patients can have low
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TABLE 1 | Patient Characteristics.

immunoglobulin levels or lymphopenia (5). In myeloid
neoplasms, granulocytes are immature or functionally impaired
(6). In addition, treatments for HM are often immunosuppressive,
which may increase the risk of infection (2, 3). However, some
studies have suggested that systemic therapy at the time of
COVID-19 infection could correlate with milder symptoms due
to an attenuated inﬂammatory response (7, 8).
Subtype of HM may also inﬂuence COVID-19 severity and
survival. One study found that patients with an acute or recent
diagnosis of HM had a higher risk of COVID-19 infection
compared to those with a chronic or established diagnosis of
HM, with the highest risk described in patients with acute
lymphoblastic leukemia (9). Initial studies in China did not
ﬁnd a signiﬁcant difference in risk of infection with COVID-19
in lymphoid compared to myeloid malignancies (10), however, a
subsequent report suggested that although patients with myeloid
malignancies may not be at a higher risk of infection they may
have worse outcomes (11). Other important risk factors for
increased mortality include older age and non-white race (12).
In summary, the current studies in patients with COVID-19
and HM have provided conﬂicting infection and survival data
and more studies in this patient population are needed. Herein,
we describe our single-center experience with COVID-19 in
patients with HM.

Characteristic, n (%)
Age (years)
• <60
• ≥60
Gender
• Female
• Male
Race
• Caucasian
• African America
• Hispanic
• Asian
History of Bone Marrow Transplant
Hematologic Malignancy
• B-cell lymphoma
• Plasma cell disorder
• Acute myeloid leukemia
• CLL/SLL
• T-cell leukemia/lymphoma
• B-cell acute lymphoblastic leukemia
• Chronic myeloid leukemia
• Myelodysplastic syndrome
• Myeloﬁbrosis
• Aplastic anemia
Active treatment
• Yes
• No
HM status
• Untreated
• Non-complete or partial remission
• Complete Remission
• Partial Remission
• Unknown
Smoking History
• Current/Former
• Never Smoker
Number of Comorbidities
• 0
• 1-3
• >3

METHODS
Study design: From March 2020 to March 2021, we collected data
within our health system on patients with HM who had a
conﬁrmed diagnosis of COVID-19. A conﬁrmed diagnosis of
COVID-19 was deﬁned as a positive result on a RT-PCR assay
of a nasopharyngeal swab specimen. Study patients were identiﬁed
by physician referral and by query of our electronic medical record
(EMR). We then retrospectively compiled epidemiological,
clinical, laboratory data, therapy details, and outcomes by
accessing EMR.
This study was approved by the institutional review board
(IRB) of Thomas Jefferson University Hospital. Patient consent
was not required given this was a retrospective and deidentiﬁed study.
Statistical analysis: The compiled data were analyzed using
descriptive measures. Median and range were used to describe
continuous variables. Frequency and percentages were used to
describe categorical variables. Mortality was calculated using
total patients who died and the study population in question.

24 (38.7%)
38 (61.3%)
25 (40.3%)
37 (59.7%)
41 (66.1%)
13 (21.0%)
6 (9.7%)
2 (3.2%)
12 (19.3%)
18 (29.0%)
16 (25.8%)
5 (8.0%)
5 (8.0%)
4 (6.4%)
4 (6.4%)
3 (4.8%)
3 (4.8%)
2 (3.2%)
2 (3.2%)
24 (38.7%)
38 (61.3%)
11 (17.7%)
20 (32.2%)
24 (38.7%)
6 (9.6%)
1 (1.6%)
35 (56.5%)
27 (43.5%)
8 (12.9%)
36 (58.1%)
18 (29.0%)

The majority of patients were over 60 years of age (61%), with
a median age of 67 years and range of 20-89 years. Lymphoid
malignancies were more common than myeloid malignancies,
with 54.8% of patients having either a B-cell lymphoma or
plasma cell disorder. Most patients had active disease and 38%
of all patients were on active treatment at the time of COVID-19
diagnosis. 38.7% of patients had mild or asymptomatic disease
that did not require hospitalization. 54.8% of patients required
hospital admission and 17.7% of patients had severe disease
requiring ICU-level care.
87% of patients had at least one comorbidity, most commonly
hypertension, obesity, cardiovascular disease, chronic kidney
disease, or autoimmune/rheumatologic disease. 56% of patients
were former or current smokers and 71% of patients who were
hospitalized had a history of tobacco use. The most common
presenting symptoms of COVID-19 were shortness of breath,
fever, cough, and fatigue. Although many patients did not have
laboratory data at the time of COVID-19 diagnosis, we found
that approximately 32% of patients for whom a complete blood
count was available (n=37) had lymphopenia.

RESULTS
More than 6,000 telehealth or in-person patient visits were
conducted for patients with HM in the Jefferson Health
Network between March 2020 and March 2021. During that
period, 62 patients with a HM had a conﬁrmed COVID-19
diagnosis. Characteristics of the patients can be found in Table 1.
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participated in a clinical trial for COVID-19 treatment
(EMPACTA; NCT04372186). In our patient cohort, no patients
were vaccinated at the time of ﬁrst COVID-19 positive test. 40.3%
(25/62) of patients were vaccinated after COVID-19 diagnosis.

In the United States, the COVID-19 pandemic can be separated
into three waves. The ﬁrst wave occurred in April 2020, the second
wave in July 2020, and the third wave occurred from November
2020 to January 2021 (13). During the ﬁrst wave, the mortality from
March to May 2020 was 27.8% (5/18). Mortality during the second
wave from June to August 2020 was 25% (1/4). For the third wave,
from September 2020 to March 2021, mortality was 10% (4/40).
Of the 62 patients diagnosed with COVID-19, 10 died (16.1%).
Mortality in hospitalized patients was 28.6%. Mortality in patients
requiring ICU level care was 60%. Mortality in patients with
myeloid malignancies was 29.4% whereas the mortality in
patients with lymphoid malignancies was 13.7%. 60% of patients
who died had an active malignancy at the time of death. 70% were
former smokers. Hypertension and cardiovascular disease were the
most common co-morbidities. Three patients transitioned to
comfort care or hospice; however, this decision was made in part
due to progression of their underlying HM and not solely due to
clinical decline from COVID-19. For the remaining 7 patients, their
cause of death was directly related to COVID-19. Table 2
summarizes the characteristics of patients with COVID-19
who died.
During the timeframe of our study, the management of
COVID-19 changed rapidly and patients received different
treatments according to evolving institutional guidelines. In our
cohort, the most common treatments included dexamethasone
(24.2%) and remdesivir (24.2%), which were often given
concurrently. 27 patients (44%) did not receive any treatment
due to asymptomatic or mild disease. Only one patient

DISCUSSION
In contrast to the published experience, we found that the number
of conﬁrmed COVID-19 in patients with HM at our center was
surprisingly low, with only 62 cases in 12 months. Possible reasons
include the early adoption of universal masking and robust
utilization of telehealth to promote social distancing at our
institution. We also report a low overall mortality rate of 16.1%.
When mortality was separated by waves, initial mortality during
the ﬁrst two waves was 27.8% and 25%, respectively. Mortality
during the third wave was lower at 10%.
Some initial reports showed mortality rates of up to 62% in
HM patients (10). However, due to study heterogeneity and
confounding factors in many studies, published case fatality and
mortality rates have been variable. The initial study published by
Wood et al. that reported data from the ASH Research
Collaborative COVID-19 Registry for Hematology demonstrated
a mortality rate of 28% in patients with HM (14). Possible reasons
for lower mortality during the third wave include an improved
understanding of COVID-19 presentation and treatment as well
as effective healthcare delivery and protocols in place to test and
treat patients.

TABLE 2 | Characteristics of Patients with HM who Died from COVID-19.
Age

72
77
84
82
53
48

HM

Nodular sclerosis Hodgkin
lymphoma
Mantle cell lymphoma
Primary myeloﬁbrosis
Acute myeloid leukemia

HM
Status

HM Treatment History

Active
Tx

CR

Doxorubicin, vinblastine, dacarbazine

No

U
N
N

None
Hydroxyurea
Decitabine, venetoclax

No
Yes
Yes

HyperCVAD + ponatinib Inotuzumab
ozogamicin Clinical trial
Rituximab, cyclophosphamide,
etoposide, vincristine, prednisone
Methotrexate/cytarabine
R-maxi-CHOP/HiDAC
AutoSCT
Rituximab
AlloSCT
Imatinib
Bortezomib/cyclophosphamide/dex
Daratumumab/velcade/dex
Elotuzumab/pomalidomide/dex
Ixazomib/lenalidomide/dex
Decitabine
AlloSCT

B-cell acute lymphoblastic
N
leukemia
Diffuse large B-cell lymphoma N

67

Mantle cell lymphoma,
Myelodysplastic syndrome

N

60

FL, CML

N

67

Amyloidosis

N

67

Secondary myeloﬁbrosis

CR

Comorbidities

Smoking
History

*Lymphopenia
(ALC <1,000 B/L)

Intubated

Former

Yes

Yes

Former
Former
Former

No
Yes
Yes

Yes
Yes
No

Yes

Emphysema, BPH,
HTN, Osteoarthritis
HTN, herpetic keratitis
CKD, HTN, GIB, PAD
HTN, HL, CAD, NICM,
GERD, CKD
CAD, Aﬁb, VT

Never

Yes

No

No

None

Former

Unknown

No

No

HTN, GERD

Never

No

Yes

Yes

PE

Former

Yes

Yes

Yes

HFpEF, sickle cell
disease, Aﬁb, HTN

Former

No

No

No

GVHD, DM, DVT,
stroke, HTN

Never

Yes

Yes

WBC, white blood cell count; CR, complete remission; U, untreated; N, non-complete or partial remission; HyperCVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; Rmaxi-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone; HiDAC, high dose cytarabine; AutoSCT, autologous stem cell transplant; AlloSCT, allogeneic stem cell
transplant; Dex, dexamethasone; BPH, benign prostatic hypertrophy; HTN, hypertension; CKD, chronic kidney disease; GIB, gastrointestinal bleed; PAD, peripheral arterial disease; HCQ,
hydroxychloroquine; HL, hyperlipidemia; CAD, coronary artery disease; NICM, non-ischemic cardiomyopathy; GERD, gastroesophageal reﬂux disease; Aﬁb, atrial ﬁbrillation; VT, ventricular
tachycardia; HFpEF, heart failure with preserved ejection fraction; GVHD, graft versus host disease; DM, diabetes mellitus; DVT, deep vein thrombosis; *Lymphopenia characterized at time
of COVID diagnosis.
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did not capture all patients with HM who were diagnosed with
COVID-19 during this time period. Since COVID-19 testing was
being performed at other local hospitals and community testing
centers it is likely that some patients were diagnosed with COVID19 outside of our institution and not reﬂected in this study. Another
limitation is that we had incomplete information for some of our
patients such as initial presenting symptoms, laboratory data, date
of COVID positive test, and cancer history available in our EMR. A
ﬁnal limitation of this study is that mortality was attributed to
COVID-19 in all patients, however, progressive HM also played a
role in several cases. The relationship between COVID-19 and
progression of malignancy is unclear.

In the United States, phase 1 of vaccinations started in December
2020 during which healthcare workers, ﬁrst responders, and those
residing in long term care facilities were eligible for vaccinations.
From January to February 2021, vaccines were available to people
older than 65 years of age. Vaccinations for people aged 16-65 with
underlying co-morbidities started in February-March 2021 (15). All
of the patients in our cohort were vaccinated after their ﬁrst positive
COVID-19 test. Vaccination likely did not contribute to decreased
mortality since all patients were vaccinated after their COVID-19
infection. It is possible that vaccinations starting in December 2020
contributed to lower number of total number of patients infected
with COVID-19. The post-covid vaccination rate was likely
underestimated given the EMR has incomplete documentation
on vaccinations.
The most common medical comorbidities in this group of
patients were hypertension, heart disease, obesity, autoimmune
disease, and chronic kidney disease. This was consistent with the
known risk factors for severe disease in COVID-19 including
cardiovascular disease, diabetes mellitus, hypertension, chronic
lung disease such as COPD and smoking, chronic kidney disease,
and obesity (16).
More than half of the patients who were diagnosed with
COVID-19 were current or former smokers. Furthermore, 7/10
of patients who died had a current or former history of tobacco use.
Other studies have correlated tobacco use to severe COVID-19
infection in the general population (17). Our study suggests that
smoking history is an important co-morbidity in patients diagnosed
with COVID-19.
In our cohort, active treatment did not appear to be a risk
factor for COVID-19 infection or mortality. 38.7% of patients
diagnosed with COVID-19 were on active treatment. Of the 10
patients who died, 5 were on active treatment.
We found that lymphoid malignancies, particularly B-cell
lymphomas and plasma cell disorders, were more common than
myeloid malignancies in our patients with COVID-19. We did not
ﬁnd that myeloid malignancies were more susceptible to COVID-19
infection and associated complications. However, it is likely that this
reﬂects our regional patient population distribution, which has higher
rates of lymphoid malignancies and multiple myeloma overall.
Larger cohort and registry studies have been underway
including COVID-19 and Cancer Consortium (CCC19), the UK
Coronavirus Cancer Monitoring Project (UKCCMP), and the
American Society of Hematology (ASH) Research Collaborative,
which will shed light on the current questions regarding HM and
COVID-19. However, it is clear that patients with HM are a
vulnerable population, and more information is needed to truly
understand the impact of COVID-19 in these patients.
Our study has several limitations. First, due to issues with
reporting and data extraction from the EMR it is likely that we

CONCLUSION
Patients with HM who develop a COVID-19 infection have a higher
case fatality rate than the general population, as demonstrated in
our cohort. However, a pair-matched analysis of patients with
COVID-19 with and without HM would help to clarify this
further. Of the patients who died, we found that smoking history
was common. It is possible that smoking history is associated with
other important co-morbidities such as cardiovascular disease,
which in turn, results in an increased risk of severe COVID-19
infection. Our study did not identify other risk factors that have
been previously reported such as lymphoid vs myeloid malignancy
and active treatment at time of infection. Given the heterogeneity of
patients with HM, more studies are needed that focus speciﬁcally on
subgroups of patients and include longitudinal follow-up.
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